Euroapi
Update in progressEAPI.PA (Paris)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates for human and veterinary medicines across Europe, North America, Asia Pacific, and beyond. It provides CDMO services for solid-phase chemistry, particle engineering, microbial fermentation, small-molecule synthesis, prostaglandins, steroids and hormones, opiates and controlled substances. Clients include pharma, generics, animal health, consumer health, nutrition, cosmetics, and biotech companies. It partners with Abolis Biotechnologies SAS for microbial strains and key intermediates. Founded in 2020, based in Paris, France.
Company score
- Sentiment
- 0.19
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.11
- Governance
- -0.03
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.07
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
No news articles are available for this company yet.
Unable to load company news.
You're all caught up!